Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Novo Nordisk Is Now A Better Value Play Than Eli Lilly With Solid Upside
06:45am, Monday, 04'th Aug 2025
Novo Nordisk is misunderstood by the market, creating a rare asymmetric value opportunity despite short-term headline pressures and a CEO transition. The company's dominant 62% global GLP-1 market sha
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
02:51pm, Sunday, 03'rd Aug 2025
LOS ANGELES--(BUSINESS WIRE)---- $NVO--NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options If you suffe
Novo Nordisk: I Was Wrong Twice, But This Selloff Looks Like 2016 All Over Again
09:30am, Sunday, 03'rd Aug 2025
I'm downgrading Novo Nordisk from Strong Buy to Buy due to recent guidance cuts, competitive pressures, and persistent compounded GLP-1 drug erosion. The long-term obesity drug opportunity, Novo's man
Why Is Novo Nordisk Stock Crashing, and Is It a Buying Opportunity?
09:00am, Saturday, 02'nd Aug 2025
Novo Nordisk (NVO 2.48%) is struggling with competition from both compounders and larger rivals.
Why Novo Nordisk Stock Bumped Higher on Friday
05:26pm, Friday, 01'st Aug 2025
Unexpected news of a potential support program from the federal government boosted the share prices of weight-loss drug developers on Friday. The poster boy for that still rather small group, Wegovy/O
The Score: Meta Platforms, Whirlpool, Novo Nordisk and More Stocks That Defined the Week
05:04pm, Friday, 01'st Aug 2025
Here are some of the major companies whose stocks moved on the week's news.
Why Novo Nordisk Stock Imploded This Week
04:00pm, Friday, 01'st Aug 2025
Shares of Novo Nordisk (NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
03:51pm, Friday, 01'st Aug 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options If you suffe
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Novo Nordisk
Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead
01:32pm, Friday, 01'st Aug 2025
Novo Nordisk stock sharply tanked this week, marking the pharmaceutical company's worst-ever weekly loss with a decline of more than 30% by Friday. This plunge extended the stock to its lowest point s
Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients
01:02pm, Friday, 01'st Aug 2025
The U.S. Food and Drug Administration approved on Friday, the Novo Nordisk A/S NVO Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episode
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
10:00am, Friday, 01'st Aug 2025
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
